Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of
thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with
mild to moderate Alzheimer's disease. This study will evaluate the effects of 24 weeks of
treatment with Thalidomide on plasma biomarkers.